Return on Assets (ROA): Twist Bioscience's ROA falls below industry averages, indicating challenges in efficiently utilizing ...

Twist Bioscience's silicon-based DNA writing platform offers competitive advantages in synthetic DNA, NGS consumables, and ...

Twist Bioscience has shown revenue growth from $54.4m in 2019 to potentially >$300m in 2024, but continues to post losses.

Twist Bioscience (NASDAQ:TWST) is scheduled to announce Q2 earnings results on Monday, May 5th, before market open. The consensus EPS Estimate is -$0.56 (+29.1% Y/Y) and the consensus Revenue Estimate ...

Twist Bioscience Corporation’s TWST share price has dipped by 5.86%, which has investors questioning if this is right time to ...

Twist Bioscience has a 1-year low of $27.41 and a 1-year high of $60.90. Twist Bioscience ( NASDAQ:TWST – Get Free Report ) last announced its quarterly earnings data on Monday, February 3rd.

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced the expanded launch of the Twist ...

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas ...

Twist Bioscience (NASDAQ:TWST) is gearing up to announce its quarterly earnings on Monday, 2025-05-05. Here's a quick overview of what investors should know before the release. Analysts are ...

Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “For customers running large scale population studies, validating genetic biomarkers or screening target therapeutics, our industry ...